A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
Public ClinicalTrials.gov record NCT05343455. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Parallel-Group, Active and Placebo Controlled Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Extended Release Capsules for the Treatment of Inflammatory Lesions of Rosacea Over 16 Weeks
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are diagnosed with moderate to severe papulopustular rosacea will be randomized in a 3:3:2 ratio to DFD-29 (40 mg), Doxycycline capsules 40 mg, or Placebo once daily for 16 weeks. Of the 320 subjects, approximately 160 subjects are planned to be enrolled at 15 sites in the US, while the remaining subjects are to be enrolled at 14 sites in the EU.
Study identification
- NCT ID
- NCT05343455
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 330 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 28, 2022
- Primary completion
- Jun 29, 2023
- Completion
- Jun 29, 2023
- Last update posted
- Dec 2, 2024
2022 – 2023
United States locations
- U.S. sites
- 15
- U.S. states
- 8
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Trial Site 15 | Santa Monica | California | 90404 | — |
| Clinical Trial Site 01 | Doral | Florida | 33178 | — |
| Clinical Trial Site 02 | Miami | Florida | 33173 | — |
| Clinical Trial Site 14 | Miami | Florida | 33175 | — |
| Clinical Trial Site 05 | Miramar | Florida | 33027 | — |
| Clinical Trial Site 08 | Clarksville | Indiana | 47129 | — |
| Clinical Trial Site 16 | Plainfield | Indiana | 46168 | — |
| Clinical Trial Site 10 | Louisville | Kentucky | 40241 | — |
| Clinical Trial Site 11 | Saint Joseph | Missouri | 64506 | — |
| Clinical Trial Site 09 | Cincinnati | Ohio | 45246 | — |
| Clinical Trial Site 04 | Dublin | Ohio | 43016 | — |
| Clinical Trial Site 06 | Anderson | South Carolina | 29621 | — |
| Clinical Trial Site 12 | Austin | Texas | 78759 | — |
| Clinical Trial Site 03 | Houston | Texas | 77056 | — |
| Clinical Trial Site 07 | Pflugerville | Texas | 78660 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05343455, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 2, 2024 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05343455 live on ClinicalTrials.gov.